The startup develops a liquid biopsy assay for early cancer detection, utilizing advanced screening technologies to analyze biomarkers in blood samples. This approach aims to improve survival rates by enabling timely diagnosis and intervention for cancer patients.
Funding
$73.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer remains a leading cause of death, and late-stage diagnosis significantly reduces survival rates. Traditional cancer detection methods often fail to identify the disease in its early, more treatable stages. There is a need for more sensitive and accessible methods for early cancer detection to improve patient outcomes.
Solution
Everest Detection is developing a liquid biopsy assay designed for the early detection of cancer. The assay analyzes biomarkers in blood samples using advanced screening technologies, aiming to identify cancer at its earliest stages when treatment is most effective. By leveraging advances in cell, molecular, and cancer biology, as well as cutting-edge detection technologies like nucleotide sequencing, single-cell detection, microRNA analysis, and proteomics, Everest Detection seeks to improve survival rates through timely diagnosis and intervention. The company partners with leading oncology clinicians and applies its technology to create products that can significantly improve patient lives.
Target Audience
The primary target audience includes individuals at high risk of cancer, oncology clinicians, and healthcare providers seeking to improve early cancer detection rates and patient outcomes.
Features
- Utilizes liquid biopsy approach for non-invasive cancer detection.
- Employs advanced screening technologies to analyze biomarkers in blood samples.
- Focuses on early-stage cancer detection to improve survival rates.
- Integrates insights from cell, molecular, and cancer biology.
- Leverages technologies such as nucleotide sequencing, single-cell detection, and proteomics.